Efficacy of low-dose apatinib combined with XELOX regimen in the treatment of advanced colon cancer
Objective To investigate the efficacy of low-dose apatinib combined with oxaliplatin + capecitabine(XE-LOX)regimen in the treatment of advanced colon cancer.Method A total of 108 patients with advanced colon cancer were divided into the control group(n=52)and the observation group(n=56)according to the different treatment regi-mens.The control group was treated with XELOX regimen,and the observation group was treated with low-dose apatinib combined with XELOX regimen.The treatment efficacy,serum tumor markers[carbohydrate antigen 72-4(CA72-4),ma-trix metalloproteinase 9(MMP9)]and vascular endothelial growth factor(VEGF)levels,intestinal flora levels,and ad-verse reactions were compared between the two groups.Result The objective response rate and disease control rate of the observation group were 57.14%(32/56)and 76.79%(43/56),respectively,which were higher than 36.54%(19/52)and 57.69%(30/52)of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CA72-4,MMP9 and VEGF in the two groups were lower than those before treatment,and the levels of CA72-4,MMP9 and VEGF in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of bifidobacterium and lactobacillus in the two groups were higher than those before treatment,and the levels of escherichia coli were lower than those before treatment,and the levels of bifido-bacterium and lactobacillus in the observation group were higher than those in the control group,and the level of esche-richia coli was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Low-dose apatinib combined with XELOX regimen can effectively improve the clinical efficacy of patients with advanced co-lon cancer,and reduce the levels of serum tumor markers and VEGF.
NETL
NSTL
万方数据
维普
